Skip to main content
Quest Diagnostics

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024

HIV-1 Drug Resistance Trends in the Era of Modern Antiretrovirals: 2018-2024

Authors: Kagan RM, Baxter JD, Kim T, Marlowe EM

Citation: Open Forum Infect Dis. 2025 Aug 4;12(8):ofaf446. doi: 10.1093/ofid/ofaf446.

Specialties: Infectious diseases

Download key summary

Related content

Audio Podcast
Screening is the First Line of Defense: Testing for Hepatitis B, Hepatitis C, & HIV
Test FAQ
HIV 1 Resistance Proviral DNA RTI PI Integrase Inhibitors
Test FAQ
HIV-1 Integrase Genotype
Test FAQ
HIV-1 Genotype
Test FAQ
HIV Pre-exposure Prophylaxis (PrEP) Testing
Conference Presentation
HIV Drug Resistance Testing for Contemporary ART

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.